The dvm360® oncology page is a comprehensive resource for clinical news and insights on the latest in veterinary oncology. This page consists of videos, interviews, articles, podcasts, and research on the advancements and developments of therapies for oncology, and more.
November 12th 2024
Canalevia-CA1 is currently the only treatment on the market for treating CID in canine patients.
September 24th 2024
FDA approves Pfizer's Palladia to treat mast-cell tumors in dogs
June 3rd 2009Rockville, Md. -- Pfizer's Palladia (Toceranib phosphate) received approval by the Food and Drug Administration (FDA). The drug is the first one developed specifically for the treatment of cancer in dogs, the FDA reported today.
Veterinary and human researchers collaborate on non-Hodgkin's lymphoma study
May 15th 2009Raleigh, N.C. -- Researchers from North Carolina State University's College of Veterinary Medicine and the University of North Carolina's Lineberger Comprehensive Cancer Center have teamed up to pinpoint the cause of and improve treatments for non-Hodgkin lymphoma in canines and humans.
Feline alimentary lymphosarcoma: A review
May 11th 2009This form of lymphoma is seen increasingly in cats, especially seniors. Two main types of alimentary lymphosarcoma affect cats: small cell and large cell. A recent article in Topics in Companion Animal Medicine reviewed the latest on diagnosing and treating both types.
Gastrointestinal neoplasms in dogs and cats (Proceedings)
April 1st 2009Primary gastrointestinal (GI) neoplasia is an important differential diagnosis for a dog or cat with vomiting or diarrhea, especially chronic vomiting or diarrhea, anorexia and weight loss, particularly animals that are middle-aged and older.
Can lomustine replace radiation therapy in treating incompletely excised mast cell tumors?
March 16th 2009Dogs with incompletely excised grade 1 and 2 mast cell tumors that are ineligible for a second surgery may undergo radiation therapy to help prevent recurrence or metastasis. But this form of therapy is expensive, inaccessible to many practitioners, and inappropriate in sensitive areas because it can cause painful skin reactions.